Register
Login:
Share:
Email Facebook Twitter

Ariana forecast 47% rise in Kiziltepe gold production Watch here

Ariana forecast 47% rise in Kiziltepe gold production


BTG Share Chat (BTG)



Share Price: 661.00Bid: 660.50Ask: 661.50Change: -2.00 (-0.30%)Faller - Btg
Spread: 1.00Spread as %: 0.15%Open: 662.00High: 667.00Low: 657.50Yesterday’s Close: 663.00


Share Discussion for BTG


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


trend364
Posts: 182
Off Topic
Opinion:No Opinion
Price:582.50
Synycom
6 Apr '18
Impairments presumably belong in the finance/accounts side so time to get a new accountant, unless of course this is a fiddle?
 
Synycom
Posts: 1,011
Off Topic
Opinion:No Opinion
Price:592.50
Over promising - again and again
5 Apr '18
Hope the CEO reads this blog. Owned this share now for 5 years. Ŷear after year it promises things are all rosy when underneath that's clearly now not the case. Product after product gets delayed when taken to market. This latest one with a £150m impairment, acting like it doesn't matter as if it's a minor balance sheet adjustment. It's not, its basically the company sitting on a problem taking in costs then suddenly making a big adjustment as if they have only just realised. If that's true the management are incompetent, if not it's been a long term coverup of a product they knew the market wasnt ready or able (legal clearances) to buy. If this bounces up a bit I am out.
trend364
Posts: 182
Off Topic
Opinion:No Opinion
Price:592.50
Way over sold
5 Apr '18
More like way way oversold. Everytime a company reports nowadays it seems to be the thing to knock it for 6 for absolutely no reason and leaves you wondering why you bothered in the first place.
SingenSmythe
Posts: 190
Off Topic
Opinion:No Opinion
Price:556.50
Way over sold
5 Apr '18
Plenty buying in at todays prices. Will be 600 again tomorrow if not today IMO
Oracle20
Posts: 351
Off Topic
Opinion:No Opinion
Price:569.00
woodford
5 Apr '18
another fine pick........
trend364
Posts: 182
Off Topic
Opinion:No Opinion
Price:653.50
SP
3 Apr '18
Bit of a red day today with market down. Hoping for good things preclose
trend364
Posts: 182
Off Topic
Opinion:No Opinion
Price:675.50
SP
5 Mar '18
Next update early April for May results. Looking at last update revenues are looking strong but not sure as to whether the company will make the leap in profits predicted for this year.
volcano
Posts: 3,615
Off Topic
Opinion:No Opinion
Price:672.50
BTG
5 Mar '18
is looking good today
Steeplejack
Posts: 184
Off Topic
Opinion:No Opinion
Price:675.00
Sunday Times article 18 Feb
19 Feb '18
Having read this piece,I feel pretty uncomfortable with my holding.I feel the company has been more than £sparing£ with the information provided to investors in recent years.Varithena is a disaster and won£t be marketed outside the USA and,in due course,a Mexican competitor could adversely hit BTGs anti venom money spinner.

After the odd hiccup,Louise Makin is sure BTGs innovative treatments will power it into the FTSE 100

Extracts-

“..........it has not been an easy couple of years.A much-hyped treatment for varicose veins was a flop,making just £1m in its first year after specialist vein clinics couldn’t get health insurers to reimburse them.Its bumbling launch in America led critics to question whether BTG had the ability to execute its shift from speciality pharmaceuticals to interventional medicine.

“They were a little bit hoist by their own petard,£says Amy Walker ,an analyst at Peel Hunt.£Their presentations from 2014 featured doorstep wedges of projections between 2014 and 2021£.By far the biggest contributor was this new treatment ,she adds.£It was meant to be the turbocharge behind the shift.£

BTG heralded the treatment-Varithena-as the biggest development in the vein market in 40 years.Makin has now slashed expectations and plans to market it only in America.

When varithena was gaining momentum in the City,BTG was tipped to be on the fast track to the FTSE 100.Its shares had risen rapidly and revenues from new growth business were expected to reach $1.25bn by 2021.Since then the stock has stalled and expectations have been set at a more modest double digit growth for new business.Total revenues reached £570.5m last year.

Makin....is elusive when asked if the hiccup has caused friction between BTG and its investors..

Today,it is interventional medicine which delivers chemotherapy directly to tumours,starved liver cancers or freezes them out completely that is earning BTG its stripes.Recent acquisitions include Roxwood,a US cardiovascular catheter maker it bought for $65m in October and Galil Medical,which treats tumours by forming an ice ball around the tissue.

While BTG is bringing an eclectic mix of new treatments to market,it is its legacy snake venom business that has funded new innovations.The treatment-Crofab-could be under threat from a Mexican competitor that has developed a different treatment.Makin,however,is relying on the peace of mind BTGs anti venom business brings........£We’ve been on the market for 12 years,so we’ve saved 60,000 lives.We’re not complacent,we’re confidently paranoid.£

Makin swerves questions about her tenure.Does she still have passion for the job?£Its taken me all this time to create the company that I want to run,and we’ve only just started.
trend364
Posts: 182
Off Topic
Opinion:No Opinion
Price:691.00
SP
5 Feb '18
Anyone know why this has fallen out of favour lately?

thanks

T




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.